An enzyme that mutates antibodies also targets a cancer-causing oncogene

Dec 11, 2008

The human immune system is in a perpetual state of self-experimentation. It expertly mutates and shuffles the DNA of its own cells to evolve new defenses against the vast array of microbes that try to invade our bodies. But when the genetic experiment goes awry, the result can be a deadly cancer.

Now, Rockefeller University scientists have discovered that the same enzyme that enables the immune system's defensive creativity is also responsible for a particular genetic malfunction — a translocation of one piece of DNA to the wrong chromosome — that causes Burkitt's lymphoma. The findings, to be published in the December 12 edition of Cell, suggest the enzyme, called activation-induced deaminase (AID), is probably involved in a broader range of cancers as well.

"We strongly suspect that many or all of the translocations of human lymphomas in mature B cells are the product of this enzyme," says Michel C. Nussenzweig, Sherman Fairchild Professor and head of the Laboratory of Molecular Immunology. "And there's more and more data to show that it may be involved in other cancers as well. It's been identified in stomach cancers, for instance."

A very specific translocation causes Burkitt's lymphoma, a cancer that plagues children in equatorial Africa. It involves a DNA break in an immune system antibody gene and the much more rare break in a cancer-promoting gene called c-myc. Previous work had shown that AID was responsible for breaking antibody genes but not c-myc. In fact, scientists thought a host of other factors might be involved in the c-myc break, but AID had been all but ruled out.

Despite the prior studies, Davide Robbiani, a research associate in Nussenzweig's lab and a Leukemia and Lymphoma Society Fellow, believed AID was the culprit. To prove it, he and his colleagues started by deleting the promoter region of the c-myc oncogene, rendering the gene inactive, in a mutant line of mice. By looking for — and not finding — the specific translocation in these mice, he showed that c-myc had to be active in order for its DNA break to take place.

He then inserted a DNA tag into the mouse genome that allowed him to induce a break at the c-myc gene, which occurs only very rarely if left to its own devices. He found that his artificially created breaks were comparable in most every way to the breaks caused by AID, but when he looked for the translocation in mice that didn't produce this enzyme, they were nowhere to be found.

"This is a definitive study," says Nussenzweig, who is also a Howard Hughes Medical Institute investigator. "We now know AID is causing damage in other parts of the genome, not just in antibody genes."

Because AID normally enables the genetic experimentation that's critical to an effective immune response, shutting it down even to fight cancer is perilous. "As a general rule, you wouldn't want to give an AID inhibitor to everyone because immune systems would not be working so well," Nussenzweig says. Still, a pharmaceutical AID inhibitor, if developed, might prove useful in treating certain tumors that are expressions of this powerful gene mutator.

The next step is to figure out exactly how AID works and identify other genetic sites where AID is active. "We are now developing the tools to do exactly that," Robbiani says.

Source: Rockefeller University

Explore further: Survival differences seen for advanced-stage laryngeal cancer

add to favorites email to friend print save as pdf

Related Stories

Bridgmanite: World's most abundant mineral finally named

55 minutes ago

A team of geologists in the U.S. has finally found an analyzable sample of the most abundant mineral in the world allowing them to give it a name: bridgmanite. In their paper published in the journal Science, the te ...

Parasitic worm genomes: largest-ever dataset released

55 minutes ago

The largest collection of helminth genomic data ever assembled has been published in the new, open-access WormBase-ParaSite. Developed jointly by EMBL-EBI and the Wellcome Trust Sanger Institute, this new ...

Recommended for you

Survival differences seen for advanced-stage laryngeal cancer

Nov 27, 2014

The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal ...

Gene test aids cancer profile

Nov 27, 2014

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.